A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)
Reassessment of Long-Term Dual Anti-Platelet Therapy Using InDividualized Strategies - Using a Novel Combined Demographic and Pharmacogenomic Strategy: The RAPID EXTEND Pilot Study
Sponsor: Ottawa Heart Institute Research Corporation
Terminated
Competing study to be started in November 2018
Other terminated trials from Ottawa Heart Institute Research Corporation
- Coronary Artery Disease · Phase NA · Nov 2023
- Cardiac Disease · Phase NA · Sep 2023
- Coronary Artery Disease · Phase NA · Sep 2022
- Hypertrophic Obstructive Cardiomyopathy · Phase PHASE3 · Apr 2022
- Covid19 · Phase NA · Aug 2021
More terminations from Ottawa Heart Institute Research Corporation
A PHASE4 clinical study on Antiplatelet Therapy and Percutaneous Coronary Intervention, this trial is terminated or withdrawn. The trial is conducted by Ottawa Heart Institute Research Corporation and has accumulated 8 data snapshots since 2017. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE4
-
Nov 2018 — Aug 2019 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ottawa Heart Institute Research Corporation
For direct contact, visit the study record on ClinicalTrials.gov .